Vironexis VNX-101 achieves MRD-negative responses in R/R ALL

Vironexis Biotherapeutics has reported that all three anti-AAV antibody-naïve patients with relapsed or refractory acute lymphoblastic leukaemia (ALL) enrolled in its Phase 1/2 SENTRY-CD19 trial have achieved measurable residual disease (MRD)-negative complete responses following a single administration of VNX-101. The San Diego-based company described the results as early but encouraging, noting that durability has been observed across all three patients, with the first remaining MRD-negative through Day 260.

VNX-101 works by delivering genetic instructions that prompt the patient's liver to produce GP101, a CD19/CD3 bispecific T-cell engaging protein. The approach is designed to combine the antitumour potency of bispecific immunotherapy with the practical advantage of a single administration, rather than the repeated infusions that characterise conventional T-cell engager regimens. One patient, who also presented with extensive extramedullary disease, achieved a complete response across all disease sites on PET imaging within 28 days. The treating physician for the first patient subsequently elected to proceed to haematopoietic stem cell transplantation while the patient remained in MRD-negative complete response, and the therapeutic protein was still detected at meaningful levels after transplant, confirming durability beyond nine months post infusion.

Safety and study scope

The safety profile recorded so far is consistent with the immune activation expected from a CD19/CD3 T-cell engager. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were observed during dose escalation and resolved fully with standard management. Vironexis said dose optimisation is continuing as part of the ongoing study. In total, nine patients have been dosed across the broader SENTRY-CD19 trial, spanning ALL, diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukaemia. The company has indicated it intends to prioritise R/R ALL as the lead indication, given the emerging clinical profile. Trial sites in South Korea have been approved and are expected to activate in the coming weeks.

VNX-101 holds FDA Fast Track, Orphan Drug, and Rare Paediatric Disease designations, a combination that may afford expedited review pathways and commercial incentives should the programme progress to a pivotal stage.

Leadership appointments and competitive context

Alongside the clinical update, Vironexis announced two notable governance additions. Kevin Sharer, who led Amgen as chief executive for more than a decade and oversaw the commercial rise of several blockbuster biologics, has been appointed Chairman of the board. Immunologist James Allison, a Nobel laureate and founding director of the James P. Allison Institute at UT MD Anderson Cancer Center, has joined the Scientific Advisory Board. Both appointments are signals of growing institutional credibility for an early-stage company.

The in vivo therapeutic protein platform that underpins VNX-101 occupies a distinct competitive space. Established CD19-directed therapies, including approved CAR-T cell products such as tisagenlecleucel and lisocabtagene maraleucel, as well as the bispecific antibody blinatumomab, require either complex cell manufacturing or continuous infusion. Vironexis is positioning VNX-101 as an off-the-shelf, one-time alternative that could address logistical and durability limitations of those approaches. Several other companies are exploring in vivo gene-delivery platforms to produce therapeutic proteins, though none has reported sustained MRD-negative responses in a haematological malignancy from a single systemic administration at this stage of clinical development. The three-patient dataset is very small and the SENTRY-CD19 study remains in dose escalation, so confirmatory data from a larger cohort will be essential before the competitive positioning can be fully assessed.

Chief executive Samit Varma said the consistency and depth of the responses "provide important clinical validation of our in vivo therapeutic protein platform," though he acknowledged the results are early. The next key milestone for investors and clinicians will be updated safety and efficacy data across the full SENTRY-CD19 patient population, expected to be presented at a forthcoming medical conference.